The company will no longer develop its medicine izokibep in two immune conditions, prioritizing instead another treatment it’s developing for thyroid eye disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,